It has been demonstrated that in epidermal growth factor receptor (EGFR)-driven lung tumors, anti-tumor immunity is inhibited by activation of the Programmed death 1 (PD-1)/Programmed death ligand 1 (PD-L1) pathway, leading to suppression of effector T cell function and increased levels of pro-inflammatory cytokines (8). Here, EGFR is linked to neoplasm.